The fragmented $8–10B drug testing market offers proven roll-up economics — consolidate regional collection networks, MRO services, and DOT consortium programs into a scalable compliance platform.
Find Drug Testing Services Platform TargetsDrug testing services remain non-discretionary across transportation, construction, healthcare, and government sectors. The market is highly fragmented with thousands of independent operators generating $1M–$5M in revenue, creating a compelling consolidation opportunity for PE-backed platforms and strategic acquirers seeking recurring, regulation-anchored cash flows.
No national independent platform dominates the collection and MRO segment. Regional operators face margin pressure from large lab networks but retain sticky employer relationships. Consolidation unlocks shared infrastructure, cross-selling of compliance services, and multiple arbitrage by scaling EBITDA from 4x to 7x+ at exit.
EBITDA of $750K–$2M with Clean Regulatory History
Target operators with auditable earnings, no DOT or SAMHSA violations, and current collector certifications that transfer cleanly to a new ownership structure.
Diversified Employer Contract Base
No single account should exceed 20% of revenue. Prioritize platforms serving transportation, construction, and healthcare with multi-year or auto-renewing employer agreements.
DOT Consortium Management and MRO Capabilities
Platforms offering both specimen collection and MRO review services generate recurring subscription-like revenue with high switching costs, anchoring long-term client retention.
Technology Infrastructure with Electronic Chain-of-Custody
Targets must operate a LIMS or digital chain-of-custody platform capable of integrating with HR and payroll systems, reducing manual overhead and enabling multi-site scalability.
Regional Collection Site Networks in Underserved Markets
Acquire operators with dense local collection site footprints or mobile fleet capabilities in geographic markets where the platform lacks same-day service coverage for employer clients.
Court-Ordered and Government Testing Contracts
Add-ons with probation, pretrial, or municipal government contracts diversify revenue beyond employer testing and add a high-volume, recurring segment resistant to private sector churn.
Standalone MRO Practices
Small Medical Review Officer practices processing results for independent collectors can be absorbed into the platform, capturing fee revenue previously paid to third-party MRO vendors.
Occupational Health Clinics with Embedded Drug Testing
Clinics where drug testing represents 30–50% of revenue offer cross-sell opportunities for DOT physicals, fit-for-duty exams, and breath alcohol testing under a bundled compliance offering.
Build your Drug Testing Services roll-up
DealFlow OS surfaces off-market Drug Testing Services targets with seller signals — the foundation of every successful roll-up.
Lab and Vendor Contract Renegotiation
Aggregating testing volume across acquired entities enables renegotiation of SAMHSA-certified lab pass-through pricing, directly expanding gross margins previously compressed by individual-operator rates.
Centralized MRO and Compliance Infrastructure
Consolidating MRO review, collector certification management, and DOT audit response into a shared services center reduces per-location overhead and eliminates owner-dependency across the portfolio.
Cross-Sell Bundled Employer Compliance Services
Existing employer relationships provide immediate cross-sell opportunities for background screening, DOT physicals, random program management, and oral fluid testing as regulatory adoption expands.
Technology Standardization and HR Platform Integration
Deploying a unified electronic chain-of-custody and result reporting system across all locations reduces manual error, accelerates result turnaround, and creates defensible switching costs for employer clients.
A scaled drug testing platform with $5M–$10M EBITDA, diversified employer contracts, and bundled MRO and DOT consortium services is positioned for acquisition by national occupational health networks, background screening companies, or laboratory services firms at 6x–8x EBITDA, representing meaningful multiple expansion over individual asset entry multiples of 3.5x–5x.
Established drug testing businesses with $750K–$2M EBITDA typically trade at 3.5x–6x, depending on client diversification, regulatory compliance record, and recurring MRO revenue as a percentage of total revenue.
Non-DOT cannabis testing volumes face pressure as states legalize recreational use, but federally regulated DOT testing mandates remain unchanged, protecting transportation and safety-sensitive employer testing volumes from legislative risk.
SBA 7(a) loans are available for initial platform acquisitions. Subsequent add-ons under a PE-backed structure typically use senior debt or seller notes, as SBA eligibility is limited once an institutional sponsor controls the entity.
Owner dependency is the primary risk. When sellers personally manage key employer accounts or perform MRO reviews, structured earnouts and 12–24 month transition agreements are essential to protect revenue post-close.
More Drug Testing Services Guides
DealFlow OS surfaces off-market platform targets with seller motivation scores. Free to join.
Find platform targets — freeNo credit card required
For Buyers
For Sellers